The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants

Blood

Volumn 124, Issue 15, 2014, Pages 2465-2466

  Tefferi, Ayalew ^a   Lasho, Terra L ^a   Tischer, Alexander ^a   Wassie, Emnet A ^a   Finke, Christy M ^a   Belachew, Alem A ^a   Ketterling, Rhett P ^a   Hanson, Curtis A ^a   Pardanani, Animesh D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; ENZYME VARIANT; JANUS KINASE 2; TRANSCRIPTION FACTOR EZH2;

ALPHA HELIX; AMINO ACID SEQUENCE; BLAST TRANSFORMATION; CALRETICULIN GENE; COMPARATIVE STUDY; DEATH; DISEASE FREE SURVIVAL; FOLLOW UP; FREQUENCY ANALYSIS; GENE; GENE FREQUENCY; GENE MUTATION; GENETIC VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LETTER; LEUKOCYTE COUNT; MYELOFIBROSIS; MYELOID METAPLASIA; SPLEEN SIZE; SPLICEOSOME; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; WILD TYPE; CHEMISTRY; GENETICS; MUTATION; PROGNOSIS; PROTEIN SECONDARY STRUCTURE; SURVIVAL;

CALRETICULIN; HUMANS; JANUS KINASE 2; MUTATION; PRIMARY MYELOFIBROSIS; PROGNOSIS; PROTEIN STRUCTURE, SECONDARY; SURVIVAL ANALYSIS;

EID: 84908065771     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-588426     Document Type: Letter

References (8)

1. Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-2390.
2. Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013; 369(25):2391-2405.
3. Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triplenegative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014;28(7):1472-1477.
4. Tefferi A, Wassie EA, Guglielmelli P, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients. Am J Hematol. 2014;89(8):E121-E124.
5. Tefferi A, Lasho TL, Finke C, et al. Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. Leukemia. 2014;28(7):1568-1570.
6. Eder-Azanza L, Navarro D, Aranaz P, Novo FJ, Cross NC, Vizmanos JL. Bioinformatic analyses of CALR mutations in myeloproliferative neoplasms support a role in signaling [published online ahead of print June 12, 2014]. Leukemia. doi: 10.1038/leu.2014.190.
7. Muñoz V, Serrano L. Development of the multiple sequence approximation within the AGADIR model of alpha-helix formation: comparison with Zimm-Bragg and Lifson-Roig formalisms. Biopolymers. 1997;41(5):495-509.
8. Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011;29(4):392-397.